A team of Northwestern scientists have developed a novel “scaffolding” biomaterial that improves bladder tissue regeneration and overall function better than current techniques.
Investigators have developed a novel approach that can better identify genetic variant interactions that are associated with increased risk of Parkinson’s disease, according to a recent study published in Brain.
Investigators led by Pinelopi Kapitsinou, MD, have discovered that inhibiting the hypoxia-driven MCT4 protein in kidney endothelial cells may halt the progression of ischemic acute kidney injury to chronic kidney disease, according to a recent study published in the Journal of Clinical Investigation.
Investigators from the laboratory of Ali Shilatifard, PhD, have developed a novel technique to precisely and efficiently study gene regulation, which may accelerate the development of new therapeutic strategies, according to a recent study published in Molecular Cell.
From probing the human brain to elucidating mechanisms behind cellular responses, Feinberg investigators have provided stunning new snapshots of biological processes invisible to the naked eye.
The use of active surveillance and watchful waiting increased from 13.2 percent in 2010 to 53.8 percent in 2020 among patients with intermediate-risk prostate cancer, according to a recent study published in JAMA.
A new blood test may help reduce unnecessary prostate biopsies and can detect prostate cancer with similar sensitivity to standard screening in patients across racial and ethnic groups, according to a recent study published in the Journal of Clinical Oncology.
Northwestern investigators, faculty, students and community partners shared and celebrated global health research, education and outreach during the 13th annual Global Health Day organized by the Robert J. Havey, MD Institute for Global Health, held on December 6.
Northwestern Medicine investigators have discovered new molecular mechanisms underlying DNA repair dysregulation in cancer cells, findings that may inform the development of new targeted therapies for patients that have become resistant to standard treatments.
Acceptance and commitment therapy significantly decreased fatigue interference and improved quality of life in patients with metastatic breast cancer six months after treatment, according to recent findings published in the Journal of Clinical Oncology.